GIA
ESPR

GHP Investment Advisors’s Esperion Therapeutics ESPR Stock Holding History

GHP Investment Advisors’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-500
Closed -$1.1K – 982
2024
Q4 		$1.1K Hold
500
– – ﹤0.01% 917
2024
Q3 		$825 Buy
+500
New +$1.01K ﹤0.01% 920

Other funds holding ESPR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PCM
PenderFund Capital Management Vancouver, British Columbia, Canada $780M AUM 24.84% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

GHP Investment Advisors's ESPR Position: Q1 2025 in Review

GHP Investment Advisors sold out of Esperion Therapeutics (ESPR) in Q1 2025, closing a stake of 500 shares — an estimated $1.1K sold.

GHP Investment Advisors first reported a position in ESPR in Q3 2024 and held it in 2 quarters. The position peaked at $1.1K in Q4 2024. 186 funds tracked by Wall St. Rank hold ESPR as of Q1 2025.

  • GHP Investment Advisors reported no remaining Esperion Therapeutics position as of Q1 2025 after selling out during the quarter.
  • GHP Investment Advisors sold 500 Esperion Therapeutics shares in Q1 2025, an estimated $1.1K.
  • GHP Investment Advisors first reported a position in Esperion Therapeutics in Q3 2024 and held it in 2 quarters.
  • GHP Investment Advisors's Esperion Therapeutics position peaked at $1.1K in Q4 2024.
  • 186 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q1 2025.

Based on GHP Investment Advisors's 13F filing for Q1 2025, filed 23 Apr 2025.